Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Angelo, Picone, Vincenzo, Martora, Fabrizio, Fabbrocini, Gabriella, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392468/
https://www.ncbi.nlm.nih.gov/pubmed/35996400
http://dx.doi.org/10.2147/CCID.S364640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392468/
https://www.ncbi.nlm.nih.gov/pubmed/35996400
http://dx.doi.org/10.2147/CCID.S364640

Ejemplares similares